Remove 2009 Remove Testimonials Remove Trials
article thumbnail

How Lume Whole Body Deodorant Was Inspired by a Genetic Disease

PLOS: DNA Science

” The Patent Trail Rather than relying on social media, company websites, and testimonials, I consulted the Patent and Trademark database to reconstruct the story of invention. The earliest patent I found was issued in late 2009, for “Products and Methods for Reducing Malodor from the Pudendum.” ” Lady parts.

Disease 83
article thumbnail

Let's Quit Sugar With Audiobook – Let's Quit Sugar

The Pharma Data

Testimonials are not necessarily representative of all of those who will use our products. Some of our testimonials are provided by customers who have received promotional offers in exchange for their participation. The testimonials displayed are given verbatim except for correction of grammatical or typing errors. 108.098194.

Disease 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analysis Life Sciences Thank You Everything the FDA is planning to do in Q3 2023

Agency IQ

to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. To implement that authority, FDA published a final rule in the Federal Register on September 15, 2015 [80 FR 55237] which revised 21 CFR 1.94

FDA 40
article thumbnail

No Expert Do-Overs

Drug & Device Law

Plaintiffs will not be heard to argue that they “could have shored up their cases by other means had they known their expert testimony would be found inadmissible.” His inability to produce admissible expert testimony is due to his own actions, namely the failure of his proposed experts to test their alternatives. Weisgram v.

article thumbnail

Dealing with the Pennsylvania Supreme Court’s Non-Decision on Standards Compliance Evidence

Drug & Device Law

A fourth Justice concurred in the result, treating the issue of standards compliance in Sullivan as a matter of evidence, and holding that the lack of a sufficient trial record supporting the relevance of the specific standards at issue in Sullivan meant that the trial judge’s exclusion was not an abuse of discretion. Ethicon, Inc. ,

article thumbnail

Plaintiffs’ Judge Shopping Ploy Fails in Bair Hugger MDL

Drug & Device Law

Assuming the expert testimony doesn’t change, the defendant essentially gets a do-over. Not surprisingly the once and future exclusion of the plaintiffs’ expert testimony loomed large in this ginned-up dispute. Evidentiary rulings in the first Bair Hugger bellwether trial that were affirmed by the Eighth Circuit. 455(a)).

article thumbnail

Another RICOdiculous Decision

Drug & Device Law

at *6 (plaintiff “has documents and formularies reaching back to only 2009”). Thus, “[o]ne supposed ‘nightmare’ trial is preferable to many hundreds of shorter ones.” This time-tested type of evidence is mostly absent from the analysis in PATDC82 II – as in Neurontin , the only actual prescriber testimony belied plaintiffs’ position.